SCHEMBL498876

SCHEMBL498876

CCCCCCCCCCCC=C(O)C=CC=CC=CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.53
EP300 Q09472 1/20 0.52
ACHE P22303 1/20 0.45
BACE1 P56817 1/20 0.45
KDM4E B2RXH2 1/20 0.44
FASN P49327 1/20 0.43
HCAR2 Q8TDS4 1/20 0.42
TERT O14746 3/20 0.42
MAPT P10636 2/20 0.42
BLM P54132 2/20 0.42
HSD17B10 Q99714 2/20 0.42
FABP4 P15090 2/20 0.42
PPARG P37231 2/20 0.42
PPARD Q03181 2/20 0.42
PPARA Q07869 2/20 0.42
GMNN O75496 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15048680 1.00 PTPN1 (0.53) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL498875 1.00 PTPN1 (0.53) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL28961749 1.00 PTPN1 (0.53) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL29991778 1.00 PTPN1 (0.53) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL15048681 1.00 PTPN1 (0.53) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL1141446 0.98 PTPN1 (0.54) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL1141447 0.98 PTPN1 (0.54) PTPN1EP300ACHEBACE1KDM4E
SCHEMBL21645848 0.89 ACHE (0.48) PTPN1EP300ACHEBACE1PPARG
SCHEMBL31203472 0.89 ACHE (0.48) PTPN1EP300ACHEBACE1PPARG
SCHEMBL29706604 0.89 ACHE (0.48) PTPN1EP300ACHEBACE1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173285-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2024-05-30 US claimed
EP-4329742-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT Amarin Pharmaceuticals Ireland Limited (IE) 2024-03-06 EP claimed
US-20230284643-A1 MILK PRODUCT COMPOSITIONS BIOMILQ INC (US) 2023-09-14 US claimed
EP-4157990-A1 MILK PRODUCT COMPOSITIONS Biomilq, Inc. (US) 2023-04-05 EP claimed
US-20230043035-A1 AGAROPHYTON CHILENSIS EXTRACT, RICH IN FREE FATTY ACIDS, AS A NUTRACEUTICAL OR NUTRITIONAL SUPPLEMENT, SUITABLE FOR MODULATING PPAR# ACTIVITY UNIVERSIDAD ANDRES BELLO (CL) 2023-02-09 US claimed
CN-115698252-A Dairy product composition 生物乳业公司 2023-02-03 CN claimed
WO-2022232633-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2022-11-03 WO claimed
WO-2022198812-A1 SEROLOGICAL MARKER FOR ASSESSING ALLERGEN-SPECIFIC IMMUNOTHERAPY EFFECT 广州医科大学附属第一医院(广州呼吸中心) 2022-09-29 WO claimed
WO-2022198813-A1 USE OF 15(S)-HYDROXYEICOSATETRAENOIC ACID IN EVALUATION OF EFFECT OF ALLERGEN SPECIFIC IMMUNOTHERAPY 广州医科大学附属第一医院(广州呼吸中心) 2022-09-29 WO claimed
US-11230704-B2 Oxidation of highly unsaturated fatty acids with novel 8-lipoxygenase derived from Malacostraca BIZEN CHEMICAL CO., LTD. (JP) 2022-01-25 US claimed
WO-2021242866-A1 MILK PRODUCT COMPOSITIONS BIOMILQ, Inc. (US) 2021-12-02 WO claimed
CN-113155996-A Use of 15(S) -hydroxyeicosatetraenoic acid for evaluating allergen specific immunotherapy efficacy 广州医科大学附属第一医院(广州呼吸中心) 2021-07-23 CN claimed
CN-113049802-A Serological marker for evaluating allergen-specific immunotherapy effect 广州医科大学附属第一医院(广州呼吸中心) 2021-06-29 CN claimed
US-20210115411-A1 NOVEL 8-LIPOXYGENASE AND USE THEREOF IWATE PREFECTURAL GOVERNMENT (JP) 2021-04-22 US claimed
WO-2014015318-A1 SOLUBLE COMPOUNDS FOR IMPROVED GENE THERAPY METHODS BLUEBIRD BIO, INC. (US) 2014-01-23 WO claimed
US-20130316989-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE RESOLVYX PHARMACEUTICALS, INC. (US) 2013-11-28 US claimed
US-20110190242-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE RESOLVYX PHARMACEUTICALS, INC. (US) 2011-08-04 US claimed
EP-1566202-A1 Use of resistin antagonists in the treatment of rheumatoid arthritis Sahltech I Göteborg AB (SE) 2005-08-24 EP claimed
WO-2003084532-A1 LIPOIC ACID ANALOGS USEFUL AS PROVITAMINS AND ANTIOXIDANTS AVERY MITCHELL A (US) 2003-10-16 WO claimed
US-20020048798-A1 Novel antioxidants AVERY MITCHELL ALLEN (US) 2002-04-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130316989-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE ALOX15B, ALOX12, ALOX15 PTPN1 3245/4885EP300 2066/4885ACHE 3371/4885
US-20110190242-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE ALOX15B, ALOX12, ALOX15 PTPN1 3245/4885EP300 2066/4885ACHE 3371/4885
US-20020048798-A1 Novel antioxidants CUTA, LIPG, NFATC1 PTPN1 1402/4885EP300 2301/4885ACHE 1167/4885
US-20230043035-A1 AGAROPHYTON CHILENSIS EXTRACT, RICH IN FREE FATTY ACIDS, AS A NUTRACEUTICAL OR NUTRITIONAL SUPPLEMENT, SUITABLE FOR MODULATING PPAR# ACTIVITY PPARG, FFAR1, PPARA PTPN1 2757/4885EP300 686/4885ACHE 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.